Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 28;11(1):914–925. doi: 10.1080/22221751.2022.2050951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Antibody response after intranasal administration of FH-001. (A) Total antibody (non-specific antibody) response from lung homogenates of FH-001 or supernatant of FH-001 treated mice. (B) FL/2006 specific antibody response from lung homogenates in FH-001 or supernatant of FH-001 treated mice. (C) Neutralization titer to FL/2006. Serum of FH-001, Al-001, or physiological saline-treated mice were tested. The microwells added with PBS rather than serum were defined as blank. (D) Hemagglutination inhibition titer to FL/2006. Serum of FH-001, Al-001, or physiological saline-treated mice were tested. The microwells added with PBS rather than serum were defined as blank. (E) Continuous total IgG₁ titer and FL/2006 specific IgG₁ titer in serums from FH-001 treated and FL/2006 challenged mice.